ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Atropine

Also written as “Atropine Sulfate”, “Low dose atropine sulfate eye drops” and “atropine sulfate”.

Its studies are mostly in Myopia · Myopia, Degenerative · Insulin Resistance · Rhinitis, Allergic, Seasonal, led by 14 companies.

Drug pageAtropine: every studyMany companies study it; this page follows only the 17 they lead. All 125 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Sep 27, 201817 company-led studies, 6 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hai Yen Eye Careits history only20 open or runningphase 1since Sep 27, 2018Sep 27, 2018none ahead
Laboratorios Sophia S.A de C.V.its history only20 open or runningphase 1since Mar 23, 2022Mar 23, 2022none ahead
Zhaoke (Guangzhou) Ophthalmology Pharmaceuticalits history only22 open or runningphase 3since Jan 5, 2024Jan 5, 2024none ahead
Cloudbreak Therapeuticsits history only10 open or runningphase 2since May 5, 2021May 5, 2021none ahead
Eyenoviaits history only10 open or runningphase 3since May 7, 2019May 7, 2019none ahead
IDB VisionCare SDN BHDits history only11 open or runningphase 3since Sep 16, 2025Sep 16, 2025Sep 2027phase 3 · NCT07329777
Kubota Pharmaceuticalits history only11 open or runningno phasesince Aug 26, 2023Aug 26, 2023none ahead
Magna Pharmaceuticalsits history only10 open or runningphase 2since Feb 26, 2014Feb 26, 2014none ahead
MicroDose Defense Productsits history only10 open or runningphase 1since Jul 22, 2009Jul 22, 2009none ahead
Ocumension Therapeutics (Suzhou)its history only10 open or runningphase 3since Nov 18, 2024Nov 18, 2024none ahead
Ocus Innovation Ireland11 open or runningphase 3since May 23, 2025May 23, 2025Dec 31, 2027phase 3 · NCT07028827
  • Named in jiangsu hengrui medicine’s own pipeline as Atropine eye drops, phase 4, as of Jul 31, 2026 (source).

Also a collaborator on its studies: Euromed Pharma Services SRL, Novotech (Australia) Pty, Source Nutraceutical and Brien Holden Vision.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2025First study: phase 3 study in MyopiaFirst studyNCT07028827 · 234 planned · Albania, Italy, Poland and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in MyopiaNCT07028827

TargetBeta

“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487

Studies

The one study Ocus Innovation Ireland leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07028827Myopia · Albania, Italy, Poland and more3RecruitingDec 31, 2027234

How it is read

Names in the registry

  • “Atropine Sulfate”, 3 entries
  • “Low dose atropine sulfate eye drops”, 3 entries
  • “atropine sulfate”, 2 entries
  • “SYD-101 0.01%”, 1 entry
  • “SYD-101 0.03%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.